MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 534934 | Name: Iomeprol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Iomeprol is a chemical agent used in X-ray imaging. It is a water-soluble, nephrotrophic, low osmolar X-ray contrast medium. Low osmolar non-ionic agents are better tolerated and less likely to cause side effects than the high osmolar ionic agents. The substance is not metabolized in the human body but excreted in unchanged form. It is decomposed slowly and can therefore accumulate in the environment.

Chemical Structure

Iomeprol
Iomeprol
CAS#78649-41-9

Theoretical Analysis

MedKoo Cat#: 534934

Name: Iomeprol

CAS#: 78649-41-9

Chemical Formula: C17H22I3N3O8

Exact Mass: 776.8541

Molecular Weight: 777.09

Elemental Analysis: C, 26.28; H, 2.85; I, 48.99; N, 5.41; O, 16.47

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Iomeprol
IUPAC/Chemical Name
1,3-Benzenedicarboxamide, N,N'-bis(2,3-dihydroxypropyl)-5-((hydroxyacetyl)methylamino)-2,4,6-triiodo-
InChi Key
NJKDOADNQSYQEV-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H22I3N3O8/c1-23(9(29)6-26)15-13(19)10(16(30)21-2-7(27)4-24)12(18)11(14(15)20)17(31)22-3-8(28)5-25/h7-8,24-28H,2-6H2,1H3,(H,21,30)(H,22,31)
SMILES Code
O=C(C1=C(I)C(N(C(CO)=O)C)=C(I)C(C(NCC(O)CO)=O)=C1I)NCC(O)CO
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 777.09 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Dooley M, Jarvis B. Iomeprol: a review of its use as a contrast medium. Drugs. 2000 May;59(5):1169-86. doi: 10.2165/00003495-200059050-00013. PMID: 10852647. 2: Rosati G. Clinical pharmacology of iomeprol. Eur J Radiol. 1994 May;18 Suppl 1:S51-60. doi: 10.1016/0720-048x(94)90094-9. PMID: 8020519. 3: García M, Aguirre U, Martinez A, Ruiz B, Lertxundi U, Aguirre C. Acute adverse reactions to iopromide vs iomeprol: a retrospective analysis of spontaneous reporting from a radiology department. Br J Radiol. 2014 Jan;87(1033):20130511. doi: 10.1259/bjr.20130511. Epub 2013 Nov 4. PMID: 24191124; PMCID: PMC4612218. 4: Xu B, Xu B, Shan S, Xue G, Wang T, Qiu X, Zhan C. Co-metabolic degradation of iomeprol by a Pseudomonas sp. and its application in biological aerated filter systems. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2018 Mar 21;53(4):310-316. doi: 10.1080/10934529.2017.1401385. Epub 2017 Dec 7. PMID: 29215947. 5: Rosati G. Clinical utility and safety profile of iomeprol. Eur J Radiol. 1994 May;18 Suppl 1:S120-4. doi: 10.1016/0720-048x(94)90106-6. PMID: 8020514. 6: Katayama H, Spinazzi A, Fouillet X, Kirchin MA, Taroni P, Davies A. Iomeprol: current and future profile of a radiocontrast agent. Invest Radiol. 2001 Feb;36(2):87-96. doi: 10.1097/00004424-200102000-00004. PMID: 11224756. 7: Ueda J, Furukawa T, Higashino K, Takahashi S, Araki Y, Sakaguchi K. Elimination of iomeprol by hemodialysis. Eur J Radiol. 1996 Nov;23(3):197-200. doi: 10.1016/s0720-048x(96)01100-x. PMID: 9003924. 8: Suh YJ, Yoon SH, Hong H, Hahn S, Kang DY, Kang HR, Choi YH, Lee W. Acute Adverse Reactions to Nonionic Iodinated Contrast Media: A Meta-Analysis. Invest Radiol. 2019 Sep;54(9):589-599. doi: 10.1097/RLI.0000000000000568. PMID: 30998567. 9: Yang X, Huang W, Liu W, Zhu Y, Xu Y, Yang G, Tang L, Zhu X. The Influence of Contrast Agent's Osmolarity on Iodine Delivery Protocol in Coronary Computed Tomography Angiography: Comparison Between Iso-Osmolar Iodixanol-320 and Low- Osmolar Iomeprol-370. J Comput Assist Tomogr. 2018 Jan/Feb;42(1):62-67. doi: 10.1097/RCT.0000000000000651. PMID: 28708716. 10: de Geeter P, Melchior H. Iomeprol versus iopromide for intravenous urography. Br J Radiol. 1994 Oct;67(802):958-63. doi: 10.1259/0007-1285-67-802-958. PMID: 8000839. 11: Machet P, Marcé D, Ziyani Y, Dumont M, Cornillier H, Jonville-Bera AP, Machet L. Acute generalized exanthematous pustulosis induced by iomeprol with cross-reactivity to other iodinated contrast agents and mild reactions after rechallenge with iopromide and oral corticosteroid premedication. Contact Dermatitis. 2019 Jul;81(1):74-76. doi: 10.1111/cod.13242. Epub 2019 Mar 14. PMID: 30762885. 12: Cipolla P, Tirone P, Luzzani F, de Haën C. Pharmacodynamic effects of iomeprol for injection in experimental animals. Eur J Radiol. 1994 May;18 Suppl 1:S32-42. doi: 10.1016/0720-048x(94)90092-2. PMID: 8020517. 13: Lorusso V, Taroni P, Alvino S, Spinazzi A. Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end- stage renal disease requiring hemodialysis. Invest Radiol. 2001 Jun;36(6):309-16. doi: 10.1097/00004424-200106000-00002. PMID: 11410750. 14: La Noce A, Bertani F, Lorusso V, Luzzani F, Tirone P, de Haën C. Preclinical safety assessment of iomeprol for injection as contrast medium for myelography. Eur J Radiol. 1994 May;18 Suppl 1:S43-50. doi: 10.1016/0720-048x(94)90093-0. PMID: 8020518. 15: Iwamoto M, Hiroshige K, Suda T, Ohta T, Ohtani A, Nakashima Y. Elimination of iomeprol in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int. 1999 Jul-Aug;19(4):380-5. PMID: 10507822. 16: Morales-Cabeza C, Roa-Medellín D, Torrado I, De Barrio M, Fernández-Álvarez C, Montes-Aceñero JF, De La Riva I, Prieto-García A. Immediate reactions to iodinated contrast media. Ann Allergy Asthma Immunol. 2017 Dec;119(6):553-557. doi: 10.1016/j.anai.2017.08.014. Epub 2017 Oct 7. PMID: 29017901. 17: Achenbach S, Paul JF, Laurent F, Becker HC, Rengo M, Caudron J, Leschka S, Vignaux O, Knobloch G, Benea G, Schlosser T, Andreu J, Cabeza B, Jacquier A, Souto M, Revel D, Qanadli SD, Cademartiri F; X-ACT Study Group. Comparative assessment of image quality for coronary CT angiography with iobitridol and two contrast agents with higher iodine concentrations: iopromide and iomeprol. A multicentre randomized double-blind trial. Eur Radiol. 2017 Feb;27(2):821-830. doi: 10.1007/s00330-016-4437-9. Epub 2016 Jun 7. Erratum in: Eur Radiol. 2017 Feb;27(2):831. PMID: 27271922; PMCID: PMC5209424. 18: Katayama H, Heneine N, van Gessel R, Taroni P, Spinazzi A. Clinical experience with iomeprol in myelography and myelo-CT: clinical pharmacology and double-blind comparisons with iopamidol, iohexol, and iotrolan. Invest Radiol. 2001 Jan;36(1):22-32. doi: 10.1097/00004424-200101000-00004. PMID: 11176258. 19: Fattori R, Piva R, Schicchi F, Pancrazi A, Gabrielli G, Marzocchi A, Piovaccari G, Blandini A, Magnani B. Iomeprol and iopamidol in cardiac angiography: a randomised, double-blind, parallel-group comparison. Eur J Radiol. 1994 May;18 Suppl 1:S61-6. doi: 10.1016/0720-048x(94)90095-7. Erratum in: Eur J Radiol 1994 Nov;19(1):72. PMID: 8020520. 20: Harder F, Schönberg SO, Sadick M. Einseitige Armschwellung – Leitsymptom einer Gefäßanomalie. Rofo. 2018 Dec;190(12):1166-1168. German. doi: 10.1055/a-0640-3442. Epub 2018 Aug 6. PMID: 30081422.